Li-Tzong Chen
National Cheng Kung University
CancerPathologyGemcitabineCancer researchMedicine
What is this?
Publications 397
#1Nai-Jung Chiang (NCKU: National Cheng Kung University)H-Index: 1
#2Ming-Huang Chen (NYMU: National Yang-Ming University)H-Index: 14
Last. Li-Tzong Chen (NCKU: National Cheng Kung University)H-Index: 38
view all 10 authors...
BACKGROUND & AIMS Gemcitabine plus cisplatin (GC) remains the standard, frontline therapy for advanced biliary tract cancer (ABTC). The JCOG1113 study suggested that the median overall survival and incidence of significant neutropenia after gemcitabine plus S-1 (GS) and GC treatments were comparable. This study evaluates the efficacy and safety of the modified GS regimen. METHODS The eligible patients with chemonaive, measurable ABTC received 800 mg/m2 of gemcitabine on day 1 and 80 mg/m2 /day o...
#1Yan Shen Shan (NCKU: National Cheng Kung University)H-Index: 22
#2Li-Tzong ChenH-Index: 38
Last. Ying-Jui Chao (NCKU: National Cheng Kung University)H-Index: 2
view all 19 authors...
Due to differences in genetic background, it is unclear whether the genetic loci identified by the previous genome-wide association studies (GWAS) of pancreatic cancer also play significant roles in the development of pancreatic cancer among the Taiwanese population. This study aimed to validate the 25 pancreatic cancer GWAS-identified single nucleotide polymorphisms (SNPs) in a case-control study (278 cases and 658 controls) of pancreatic cancer conducted in Taiwan. Statistical analyses were co...
#1Li-Tzong Chen (NHRI: National Health Research Institutes)H-Index: 38
#1Yang Yi-Hsin (NHRI: National Health Research Institutes)
#2Li-Tzong Chen (NHRI: National Health Research Institutes)H-Index: 38
Last. Shiu-Feng Huang (NHRI: National Health Research Institutes)H-Index: 1
view all 3 authors...
#1Yung-Yeh Su (NCKU: National Cheng Kung University)H-Index: 1
#2Nai-Jung Chiang (NCKU: National Cheng Kung University)H-Index: 1
Last. Li-Tzong Chen (NCKU: National Cheng Kung University)H-Index: 38
view all 6 authors...
Liposomal irinotecan plus 5-fluorouracil/leucovorin (nal-IRI + 5-FU/LV) has shown to provide survival benefits for patients with gemcitabine-refractory metastatic pancreatic ductal adenocarcinoma (PDAC) in NAPOLI-1 trial, in which Asian patients experienced more hematological toxicity and subsequent dose modification. A retrospective chart review to investigate the administration pattern, therapeutic efficacy and safety profile of nal-IRI + 5-FU/LV in 44 consecutive patients with gemcitabine-ref...
1 CitationsSource
#1Li-Tzong Chen (NCKU: National Cheng Kung University)H-Index: 38
#2Taroh Satoh (Osaka University)H-Index: 22
Last. Narikazu BokuH-Index: 50
view all 25 authors...
Background Nivolumab showed improvement in overall survival (OS) in ATTRACTION-2, the first phase 3 study in patients with gastric/gastroesophageal junction (G/GEJ) cancer treated with ≥ 2 chemotherapy regimens. The 2-year follow-up results of ATTRACTION-2 are presented herein.
1 CitationsSource
#1Changhoon Yoo (UOU: University of Ulsan)H-Index: 17
#2Do Youn Oh (Seoul National University Hospital)H-Index: 21
Last. Isabelle Dussault (Merck Serono)H-Index: 3
view all 11 authors...
Background Patients with biliary tract cancer (BTC) have poor prognosis with few treatment options. Bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain of the transforming growth factor (TGF)-βRII receptor (a TGF-β ‘trap’) fused to a human IgG1 antibody blocking programmed death ligand 1 (PD-L1), has shown clinical efficacy in multiple solid tumors. Methods In this phase I, open-label trial expansion cohort, Asian patients with BTC whose disease pro...
#1Johann S. de Bono (The Royal Marsden NHS Foundation Trust)H-Index: 101
#2Chia-Chi Lin (NTU: National Taiwan University)H-Index: 27
Last. James Chih-Hsin Yang (NTU: National Taiwan University)H-Index: 107
view all 23 authors...
Xentuzumab, an insulin-like growth factor (IGF)-1/IGF-2-neutralising antibody, binds IGF-1 and IGF-2, inhibiting their growth-promoting signalling. Two first-in-human trials assessed the maximum-tolerated/relevant biological dose (MTD/RBD), safety, pharmacokinetics, pharmacodynamics, and activity of xentuzumab in advanced/metastatic solid cancers. These phase 1, open-label trials comprised dose-finding (part I; 3 + 3 design) and expansion cohorts (part II; selected tumours; RBD [weekly dosing])....
1 CitationsSource
#1Li-Tzong Chen (NCKU: National Cheng Kung University)H-Index: 38
#1L Chen (NCKU: National Cheng Kung University)H-Index: 3
Last. J.-Y. DouillardH-Index: 23
view all 29 authors...
Abstract The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of hepatocellular carcinoma (HCC) was published in 2018, and covered the diagnosis, management, treatment and follow-up of early, intermediate and advanced disease. At the ESMO Asia Meeting in November 2018 it was decided by both the ESMO and the Taiwan Oncology Society (TOS) to convene a special guidelines meeting immediately after the Taiw...
1 CitationsSource
#1Juan W. ValleH-Index: 43
#2Li Yuan Bai (PRC: China Medical University (PRC))H-Index: 19
Last. Harpreet Wasan (Hammersmith Hospital)H-Index: 40
view all 19 authors...
477Background: We assessed RAM or MER plus standard of care GEM+CIS as first-line treatment for BTC. Methods: Patients (pts) with BTC, ECOG PS 0/1, and measurable disease were randomized 2:1:2:1 to...
2 CitationsSource